Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer

[1]  John W. Scott,et al.  A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. , 2015, European urology.

[2]  Anamaria Crisan,et al.  Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. , 2015, European urology.

[3]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[4]  Pierre Mozer,et al.  First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancer , 2015, BJU international.

[5]  A. Svindland,et al.  Detection of the index tumour and tumour volume in prostate cancer using T2‐weighted and diffusion‐weighted magnetic resonance imaging (MRI) alone , 2014, BJU international.

[6]  M. Shipitsin,et al.  Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality , 2014, Proteome Science.

[7]  L. van Neste,et al.  Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. , 2014, American health & drug benefits.

[8]  Francesco Montorsi,et al.  Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Catalona,et al.  The Prostate Health Index: a new test for the detection of prostate cancer , 2014, Therapeutic advances in urology.

[10]  T. D. de Reijke,et al.  Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.

[11]  Young Hwan Kim,et al.  Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. , 2014, Radiology.

[12]  C. Moore,et al.  Role of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer , 2014, International journal of urology : official journal of the Japanese Urological Association.

[13]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[14]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[15]  P. Choyke,et al.  Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. , 2013, The Journal of urology.

[16]  C. Miranti,et al.  Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development , 2013, Front. Oncol..

[17]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[18]  Jan van der Meulen,et al.  Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. , 2013, Radiology.

[19]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[20]  G. Palomaki,et al.  Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. , 2013, The Journal of urology.

[21]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[22]  P. Mozer,et al.  Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. , 2012, European urology.

[23]  T. Scheenen,et al.  Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. , 2012, Radiology.

[24]  Baris Turkbey,et al.  Correlation of magnetic resonance imaging tumor volume with histopathology. , 2012, The Journal of urology.

[25]  Z. Jia,et al.  Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse , 2012, PloS one.

[26]  B. Trock,et al.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies , 2012, BJU international.

[27]  J. Cuzick,et al.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort , 2012, British Journal of Cancer.

[28]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[29]  Thomas Hambrock,et al.  Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. , 2011, Radiology.

[30]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[31]  S. Verma,et al.  Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.

[32]  Katsuyuki Nakanishi,et al.  Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer? , 2011, Journal of magnetic resonance imaging : JMRI.

[33]  L. Klotz,et al.  Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay , 2010, Prostate Cancer and Prostatic Diseases.

[34]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[35]  A. Prando.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume , 2009 .

[36]  H. D. de Koning,et al.  Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer , 2009, British Journal of Cancer.

[37]  Jason A Koutcher,et al.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. , 2009, Radiology.

[38]  P. Humphrey,et al.  Loss-of-Nkx3.1 Leads to Activation of Discrete Downstream Target Genes during Prostate Tumorigenesis , 2009, Oncogene.

[39]  M. Cooperberg,et al.  Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. , 2009, Journal of the National Cancer Institute.

[40]  A. D. De Marzo,et al.  Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.

[41]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[42]  Katsuyoshi Ito,et al.  Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade , 2008, Journal of magnetic resonance imaging : JMRI.

[43]  Andrew J Vickers,et al.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden , 2008, BMC medicine.

[44]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[45]  D. Bostwick,et al.  Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. , 2007, Urology.

[46]  G. Beaudry,et al.  Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization , 2007, Modern Pathology.

[47]  Rodolfo Montironi,et al.  Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. , 2007, European urology.

[48]  Jurgen J Fütterer,et al.  MR imaging in local staging of prostate cancer. , 2007, European journal of radiology.

[49]  Adam S. Kibel,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007 .

[50]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[51]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[52]  C. Kim,et al.  Localization of Prostate Cancer Using 3T MRI: Comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging , 2006, Journal of computer assisted tomography.

[53]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[54]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[55]  J. McNeal.  Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. , 1992, Human pathology.

[56]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[57]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[58]  R. Maria,et al.  MicroRNAs and prostate cancer. , 2010, Endocrine-related cancer.

[59]  H. Hricak,et al.  Imaging of prostate cancer. , 2007, Radiologic clinics of North America.